Previously, Shanghai medicine had issued a performance report for 2022. During the reporting period, the company achieved operating income of $231.981 million, an increase of 7.49 per cent over the same period; net profits belonging to shareholders of listed companies of $5617 million, an increase of 10.28 per cent over the same period. This good performance, of course, cannot be overtaken by the top management of the company, and the Managing Director of Shanghai Medicine has attracted the a...
